Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04778644 · ClinicalTrials.gov registry record · Phase 1
Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task
A Phase 1 study of CBD, sponsored by Hartford Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04778644: Active Phase 1 study of CBD, sponsored by Hartford Hospital.
NCT04778644 is a Phase 1 study of CBD that is active but no longer recruiting, run by Hartford Hospital. The registered enrollment target is 20 participants, below the 65-participant average among 8 other CBD trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04778644, a Phase 1 study of CBD, is active but no longer recruiting, sponsored by Hartford Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabidiol (CBD) is another cannabis plant derivative for which, like THC, there has been extensive research. Unlike THC however, CBD is non-intoxicating and non-psychedelic. CBD has antipsychotic effects. Logically, if CBD opposes THC effects, it may be a potential antipsychotic treatment. The purpose of this pilot research is to show target engagement of the hippocampus with the study drug (CBD versus placebo) in patients who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychosis compared to healthy controls.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CBD
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 1 |
What the registry record for NCT04778644 still lists
NCT04778644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 65-participant average among 8 other CBD trials with a reported enrollment target (69% lower).
The record links to 1 condition, with CBD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04778644 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04778644 about?
NCT04778644 is a clinical study titled "Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task". Cannabidiol (CBD) is another cannabis plant derivative for which, like THC, there has been extensive research. Unlike THC however, CBD is non-intoxicating and non-psychedelic. CBD has antipsychotic effects. Logically, if CBD opposes THC effects, it may be a potential antipsychotic treatment. The pur...
What is the current status of trial NCT04778644?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-12-15. Estimated completion is 2025-12-15.
What conditions does trial NCT04778644 study?
This clinical trial studies the following conditions: CBD.
What interventions are being tested in trial NCT04778644?
The interventions under investigation include: Placebo (DRUG), CBD (DRUG).
Who is sponsoring clinical trial NCT04778644?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04778644 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CBD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04778644's enrollment target sits among peer trials
20 7th of 8 higher than 2 of 8 other CBD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other CBD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
COMPLETED · Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms
RECRUITING · NA
-
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
ACTIVE NOT RECRUITING
-
RCT of CBD for Anxiety in Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI